Equity Overview
Price & Market Data
Price: $8.45
Daily Change: -$0.07 / 0.83%
Range: $8.16 - $8.84
Market Cap: $730,385,856
Volume: 1,635,417
Performance Metrics
1 Week: 6.19%
1 Month: 18.48%
3 Months: -15.58%
6 Months: -28.27%
1 Year: -42.70%
YTD: -20.90%
Company Details
Employees: 118
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.